Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Zoldan
J
J
Department of Neurology, Beilinson Medical Center, Petah Tiqva, Israel.
Friedberg
G
G
Weizman
A
A
Melamed
E
E
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003702:Delusions / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D012702:Serotonin Antagonists; D007980:Levodopa; D017294:Ondansetron